Sorrento Therapeutics (NASDAQ:SRNE) was upgraded by equities researchers at ValuEngine from a “strong sell” rating to a “sell” rating in a report released on Wednesday, January 3rd.
A number of other research analysts have also recently issued reports on SRNE. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Sorrento Therapeutics in a research note on Monday, September 18th. Oppenheimer set a $6.00 target price on shares of Sorrento Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, November 15th. Finally, BidaskClub raised shares of Sorrento Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, December 20th. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. Sorrento Therapeutics presently has an average rating of “Buy” and a consensus target price of $11.50.
Shares of Sorrento Therapeutics (NASDAQ:SRNE) traded up $0.32 during trading hours on Wednesday, reaching $5.00. 1,321,800 shares of the company were exchanged, compared to its average volume of 1,870,000. The company has a market capitalization of $396.61, a PE ratio of -11.90 and a beta of 1.04. The company has a debt-to-equity ratio of 0.18, a current ratio of 0.54 and a quick ratio of 0.54. Sorrento Therapeutics has a fifty-two week low of $1.50 and a fifty-two week high of $5.95.
TRADEMARK VIOLATION NOTICE: This piece was originally reported by Week Herald and is the sole property of of Week Herald. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://weekherald.com/2018/01/12/sorrento-therapeutics-srne-upgraded-by-valuengine-to-sell.html.
About Sorrento Therapeutics
Sorrento Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Sorrento Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.